Background and purpose: To investigate the molecular mechanism for the effect of auranofin on the induction of cell differentiation, the cellular events associated with differentiation were analysed in acute promyelocytic leukaemia (APL) cells. Experimental approach: The APL blasts from leukaemia patients and NB4 cells were cotreated with auroanofin and all-transretinoic acid (ATRA) at suboptimal concentration. The HL-60 cells were treated with auroanofin and a subeffective dose of 1a,25-dihydroxyvitamin D 3 (1,25(OH) 2 vit D 3 ) in combination. The effect of auroanofin was investigated on histone acetylation at the promoter of differentiation-associated genes and expression of cell cycle regulators. Key results: Treatment with auroanofin and ATRA cooperatively induced granulocytic differentiation of fresh APL blasts isolated from patients and NB4 cells. The combined treatment also increased reorganization of nuclear PML bodies and histone acetylation at the promoter of the RARb2 gene. Auroanofin also promoted monocytic differentiation of the HL-60 cells triggered by subeffective concentration of 1,25(OH) 2 vit D 3 . The combined treatment of auroanofin and 1,25(OH) 2 vit D 3 stimulated histone acetylation at p21 promoters and increased the accumulation of cells in the G 0 /G 1 phase. Consistent with this, the expressions of p21, p27 and PTEN were increased and the levels of cyclin A, Cdk2 and Cdk4 were decreased. Furthermore, the hypophosphorylated form of pRb was markedly increased in cotreated cells. Conclusions and implications: These findings indicate that auroanofin in combination with low doses of either ATRA or 1,25(OH) 2 vit D 3 promotes APL cell differentiation by enhancing histone acetylation and the expression of differentiationassociated genes.
Introduction
All-trans-retinoic acid (ATRA), which has been used as a therapeutic drug for acute promyelocytic leukaemia (APL), acts by binding to its nuclear receptor, retinoic acid receptor (RAR)/retinoid X receptor (RXR) (Warrell et al., 1993) . The RAR/RXR heterodimer binds to the retinoic acid response element (RARE) sites of its target genes and acts as a ligandinducible transcription factor. In the absence of ATRA, the receptor associates with the nuclear corepressor N-CoR/ histone deacetylase complex, which turns off the transcription. Occupation of the receptor by ATRA displaces the corepressor complex to the transcriptional coactivator complex, which includes histone acetyltransferase and leads to histone acetylation and expression of target genes (Mu et al., 1994; Piazza et al., 2001 ).
APL produces the characteristic promyelocytic leukaemia (PML)-RARa fusion protein through a reciprocal chromosome translocation between the PML gene on chromosome 15 and the RARa gene on chromosome 17 (Lavau and Dejean, 1994) . In APL cells, PML-RARa binds to RARE instead of RARa. Because the interaction of PML-RARa fusion protein with the corepressor complex is strong, the corepressor complex is not converted to the coactivator complex, with physiological concentrations of ATRA (Grignani et al., 1994; Guidez et al., 1998) . As a result, the transcriptions of RARa target genes, which are associated with cell differentiation, are constitutively repressed and the differentiation of promyelocytic progenitor cells towards mature cells is not induced (Tallman et al., 1997) .
A pharmacologically high concentration of ATRA can overcome this failure and induces expression of differentiation-associated genes. For this reason, differentiation-inducing therapy with a high dose of ATRA has been used clinically to treat APL patients (Huang et al., 1988) . Although ATRA therapy is effective in inducing remission, its major problem is that most relapsed APL patients are resistant to further treatment with ATRA (Degos et al., 1990; Douer, 2002) .
Other differentiation-inducing agents have been investigated. Among them, 1a, (1,25(OH) 2 vit D 3 ), a physiologically active form of vitamin D 3 , induces differentiation of myeloid leukaemic cells along the monocyte/macrophage lineage (Abe et al., 1981) . The biological response to 1,25(OH) 2 vit D 3 is mediated through its nuclear vitamin D receptor, a ligand-inducible transcription factor (Kato, 2000) . However, clinical trials of high doses of 1,25(OH) 2 vit D 3 for treating leukaemia have been limited because of the hypercalcemic side effect and incomplete cell differentiation (Evans, 1988) .
A major goal in therapeutic strategies for treating patients with APL is to achieve terminal differentiation and to solve the problems of drug resistance and harmful side effects. One useful strategy is combined treatment with ATRA or 1,25(OH) 2 vit D 3 at low doses, which does not induce toxicity, along with another drug, so that the two drugs act synergistically.
Auranofin (2, 3, 4 and 6-tetra-O-acetyl-1-thio-b-D-glucopyranosato-S-(triethylphosphine) gold) is a lipophilic gold compound, used to treat rheumatoid arthritis, based on its anti-inflammatory property (Blodgett et al., 1984; Borg et al., 1988) . The drug inhibits the production of proinflammatory cytokines such as interleukin-1b and tumour necrosis factora through inactivation of nuclear factor-kB (Jeon et al., 2000) , and blocks interleukin-6 signalling by inhibiting phosphorylation of janus kinase 1 (JAK1) and signal transducer and activator of transcription 3 (STAT3) (Kim et al., 2007) . We found recently that auroanofin has a novel antileukaemic activity in NB4 cells, inducing apoptosis at relatively high concentrations (1-2 mM) and cell differentiation at lower concentrations (0.3-0.5 mM) by acting synergistically with a physiological concentration of ATRA (5 nM) (Kim et al., 2004; Park and Kim, 2005) .
To investigate the molecular mechanisms underlying the stimulatory effect of auroanofin on APL cell differentiation, we used auroanofin in combination with low doses of ATRA or 1,25(OH) 2 vit D 3 to treat primary APL cells isolated from patients and the APL cell lines (NB4 and HL-60) and then analysed the histone acetylation at the promoter regions of differentiation-associated genes.
Methods
Cell culture and treatment This study was approved by the Institutional Review Board of the Catholic University of Korea, Seoul. Fresh APL blasts were isolated from the bone marrow of four patients bearing leukaemia at St Mary's Hospital, Seoul (Table 1) ; all patients signed a written consent form to donate the bone marrow for research. After gradient centrifugation using histopaque-1077, the monocytes were eliminated by removing the adherent cells. The non-adherent leukaemic cell fraction was used as a source of fresh APL blasts. NB4 cells and HL-60 cells were maintained at 37 1C in 5% CO 2 atmosphere in RPMI 1640 medium supplemented with 2 mM L-gluatmine, 10 mM Hepes, 100 UmL À1 Penicillin, 100 mg mL À1 Streptomycin, and 10% heat-inactivated fetal bovine serum (Gibco Life Technology, Gaithersburg, MD, USA).
To investigate the effect of auroanofin on granulocytic differentiation, the fresh APL blasts and NB4 cells were seeded (1 Â 10 6 cells) in 10 cm dishes and incubated for 4-5 days in medium containing auroanofin (0.3-0.5 mM) and ATRA (10 nM). To analyse monocytic differentiation, 2 Â 10 6 HL-60 cells were incubated for 3 days in the presence of auroanofin (0.5 mM) and 1,25(OH) 2 vit D 3 (3 nM).
Evaluation of cell differentiation Induction of cell differentiation was evaluated by measuring the morphological changes, nitroblue tetrazolium (NBT) reduction and expression of surface antigen markers (CD11b and CD14). To observe morphological changes, the incubated cells were collected on glass slides by cytospin centrifugation. Cells were fixed in methanol, stained with 
Cell cycle progression
The HL-60 cells treated with auroanofin or 1,25(OH) 2 vit D 3 or both were washed with cold PBS, pelleted and fixed with 80% ethanol in PBS. The cells were resuspended in 1 mL of PBS containing 50 mg mL
À1
propidium iodide and 100 mg mL À1 DNase-free RNase A and incubated at 37 1C
with agitation for 30 min. The propidium iodide -stained cells were analysed using an FACScan flow cytometer.
Western blot analysis
Cells were washed twice with PBS and lysed in lysis buffer containing 25 mM Tris-HCl (pH 7.2), 0.1% SDS, 0.1% Triton X-100, 1% sodium deoxycholate, 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid1 mM Na 3 VO 4 , 1 mM phenylmethylsulphonyl fluoride, 10 mg mL
À1
aprotinin and 5 mg mL À1 leupeptin for 20 min on ice. The nuclear extracts were prepared by the method described earlier (Kim et al., 2007) . Equal protein amounts of total cell lysates or nuclear extracts were separated on a 12% SDS-polyacrylamide gel and analysed with various human antibodies. Antibodies against p21, p27, PTEN, cyclin A, cyclin-dependent kinase 2 (Cdk2), Cdk4, PML and hypophosphorylated retinoblastoma protein (pRb) were used as the primary antibodies. The proteins of interest were visualized using an enhanced chemiluminescence-based detection system (AmershamPharmacia Biotech, Piscataway, NJ, USA). 
Control

RNA isolation and reverse transcription PCR (RT-PCR)
Total RNA was extracted using RNA STAT-60 solution according to the manufacturer's instruction (TEL-TEST, Friends-wood, TX, USA). A unit of 1 mg of total RNA was reverse transcribed for cDNA using Molony Murine Leukaemia Virus reverse transcriptase (Promega Corporation, Madison, WI, USA). The reaction was carried out at 42 1C for 1 h. The cDNAs for p21 and RARb2 were amplified using specific primers (p21: sense 5 0 -CCGTGTTCTCCTTTTCCTCTCTCC-3 0 , antisense 5 0 -GAAAGATCTACTCC CCCATCATATACC-3 0 , RARb2: sense 5 0 -AACGCGAGCGATCCGAGCAG-3 0 , antisense 5 0 -ATTTG TCCTGGCAGACGAAGCA as follows: 30 cycles at 94 1C for 1 min, 60 1C for 1 min, 72 1C for 1 min. The PCR products were separated on 1.2% agarose gel and stained with ethidium bromide.
Chromatin immunoprecipitation (ChIP) assay A ChIP assay was performed using a ChIP assay kit according to the manufacturer's protocol (Upstate Biotechnology, Lake Placid, NY, USA). Briefly, 2 Â 10 6 cells were treated with auroanofin and ATRA or auroanofin and 1,25(OH) 2 vit D 3 and fixed with 1% formaldehyde for 10 min. The cells were lysed in cell lysis buffer for 10 min on ice. The lysates were sheared by sonication and then the sonicated cell supernatants were precleared for 2 h at 4 1C with salmon sperm DNA-saturated protein A agarose. A small amount of each sample was reserved for using as an input DNA control in PCR analysis. Samples were divided into two fractions and immunoprecipitated with antiacetyl histone H3-specific antibody and with antihuman IgG-negative control antibody. The protein-DNA complex was treated with 1% SDS in 0.1 M NaHCO 3 and incubated at 65 1C for 4 h to reverse the cross-links. The DNA was extracted, and the promoter regions of RARb2 and p21 were amplified with the specific primers by PCR. The primers were: RARb2, sense 5 0 -TCCTGGGAGTTGGTGATGTCAG-3 0 , antisense 5 0 -AAAC CCTGCTCGGATCGCTC-3 0 ; and p21, sense 5 0 -GCACTCTGG AGGAGGACACA-3 0 ; antisense 5 0 -GCCAGCTCTCGCACT CTGT T-3 0 .
Statistical analysis
Student's t-test and one-way ANOVA were used to analyse the differences between values obtained in the various experimental and control conditions; Po0.05 was considered significant. 
Materials
Results
Combined effects of auroanofin and ATRA on granulocytic differentiation of APL cells isolated from patients Our previous study showed that auroanofin enhances the differentiation of NB4 cells in the presence of subeffective concentrations of ATRA that alone could not induce significant cell differentiation (Kim et al., 2004) . Although the NB4 cell line is derived from an APL patient, its characteristics are not the same as those of primary APL cells. To confirm whether auroanofin also has stimulatory effects on the differentiation of primary APL cells, fresh APL blasts were purified from bone marrows of APL patients (Table 1) . The primary APL cells were incubated for 5 days in medium containing auroanofin (0.5 mM) and ATRA (10 nM). The cells were stained with Giemsa solution and the morphological changes were observed in a microscope. Untreated primary APL cells were predominantly promyelocytes with round and regularly shaped nuclei. The cells treated with auroanofin and ATRA together showed features of granulocytic differentiation, such as nuclear lobulation, numerous granules and vacuoles and a lower ratio of nucleus to cytoplasm; in contrast, the cells treated with auroanofin or ATRA alone showed weak differentiation (Figure 1) .
To further study the induction of differentiation by auroanofin, quantitative flow cytometric analysis of CD11b surface antigen and the NBT reduction test were performed. The expression of CD11b increased more after combined treatment with auroanofin (0.5 mM) and ATRA (10 nM) than after treatment with auroanofin or ATRA alone (Figure 2a ).
Consistent with these results, the formation of formazan by NBT reduction was increased when the APL blasts were treated with the combination of auroanofin and ATRA (Figure 2b ). These findings suggest that, in primary APL blasts, auroanofin prompts granulocytic differentiation, which is triggered by subeffective dose of ATRA.
Reorganization of nuclear PML body and degradation of PML-RARa PML protein is normally localized in specific subnuclear domains characterized by PML bodies. However, in APL cells, PML and PML-RARa proteins are colocalized throughout the nucleoplasm in a micropunctate pattern (Daniel et al., 1993) . Treatment of the APL cells with ATRA at pharmacologically high concentration induces a degradation of PML-RARa protein and reorganizes the PML bodies (Dyck et al., 1994; Yoshida et al., 1996) . We examined whether auroanofin acts in the processes of degradation of the PML-RARa fusion protein and reconstitution of the PML bodies. When the localization of PML and PML-RARa was observed by confocal microscopy, immunofluorescence-staining patterns of PML showed diffusely throughout the nucleoplasm in primary APL cells from patients ( Figure 3A , a) and the NB4 cells ( Figure 3B , f). In contrast, the cells treated with both auroanofin and ATRA showed an apparent speckled pattern ( Figures 3A, d and 3B, i) similar to the pattern of positive controls of cells treated with a high dose of ATRA (1000 nM) (Figures 3A, e and 3B, j), suggesting that PML protein relocalizes to the nuclear PML body. The cotreatment with auroanofin and ATRA also decreased PML-RARa protein (110 kDa) level ( Figure 3D ). These findings suggest that auroanofin and ATRA cooperate in degradation of PMLRARa and reorganization of PML body in APL cells.
Effect of auroanofin on histone acetylation at promoter of the RARb2 gene
The PML-RARa fusion protein, bound on RARE sites of the ATRA-target promoters, recruits histone deacetylase complex and blocks the transcriptions of the target genes (Di Croce, 2005) . Because auroanofin was involved in PML-RARa degradation, we examined whether auroanofin could restore the histone acetylation around the promoter of the RARb2 gene, which is an ATRA target and plays a crucial role in APL cell differentiation (Lin et al., 1998; Fazi et al., 2005) . The ChIP assay using an antiacetylated histone H3 antibody showed that the histone acetylation at the RARb2 gene promoter increased significantly in APL cells differentiated by cotreatment with auroanofin and ATRA in low doses (Figure 4b ). Consistent with this, the transcription of RARb2 also increased (Figure 4c ). These results suggest that auroanofin acts synergistically with a suboptimal dose of ATRA to restore histone acetylation and to upregulate the expression of differentiation-associated genes, leading to APL cell differentiation.
Enhancement of monocytic differentiation by combined treatment with auroanofin and 1,25(OH) 2 vit D 3
The HL-60 cell line has been used widely as a model system of APL differentiation, because high doses of ATRA or 1,25(OH) 2 vit D 3 induce terminal differentiation toward granulocytes or monocytes, respectively (Breitman et al., 1980; McCarthy et al., 1983) . To investigate whether auroanofin also stimulated 1,25(OH) 2 vit D 3 -mediated monocytic differentiation, HL-60 cells were treated for 3 days with auroanofin (0.5 mM) or 1,25(OH) 2 vit D 3 (3 nM) or both. The NBT reduction assay indicated that the combined treatment induced differentiation to the same extent as treatment with 1,25(OH) 2 vit D 3 (100 nM, positive control) ( Figure 5a ). The expression of CD14 surface antigen, a marker of monocytes/macrophages, was also detected. As shown in Figure 5b , combined treatment with auroanofin and 1,25(OH) 2 vit D 3 markedly increased antigen expression (81%), in contrast to the low expression induced by auroanofin (0.6%) or 1,25(OH) 2 vit D 3 (15%) alone. These results suggest that auroanofin also contributes to the monocytic differentiation of HL-60 cells.
Analysis of the cell cycle and cell cycle regulators
Cell differentiation is associated with G 0 /G 1 arrest (Furukawa, 2002) . To determine the effect of auroanofin on cell cycle progression, flow cytometric analysis of propidium iodide-stained nuclei was carried out. As shown in Figure 6 , the accumulation of cells in the G 0 /G 1 phase increased more after treatment with the combination of auroanofin and 1,25(OH) 2 vit D 3 than with each compound alone. The number of cells in the S phase decreased concomitantly. Because the cell cycle is controlled by cyclins and Cdks, the expression of these regulators was measured. Figure 7a indicates that the expression levels of p21, p27 and PTEN increased and the levels of cyclin A, Cdk2 and Cdk4 decreased in cotreated cells. The pRb protein is also an inhibitor of cell cycle progression and, in G 0 /G 1 -arrested cells, pRb mainly exists in hypophosphorylated form, whereas pRb is hyperphosphorylated by G 1 /S-Cdks in actively proliferating conditions (Hollingsworth et al., 1993) . We also examined the phosphorylation states of pRb in untreated and auroanofin/1,25(OH) 2 vit D 3 -treated HL-60 cells. The cells treated without and with auroanofin (0.5 mM) or 1,25(OH) 2 vit D 3 (3 nM) showed little hypophosphorylated pRb. However, the hypophosphorylated pRb was markedly increased in combined treatment with auroanofin and 1,25(OH) 2 vit D 3 , to a similar extent as a positive control (100 nM 1,25(OH) 2 vit D 3 ) (Figure 7b ). These findings suggest that auroanofin and 1,25(OH) 2 vit D 3 acts synergistically on cell cycle arrest at G 0 /G 1 phase. Effect of auroanofin on acetylation of histone around the promoter of the p21 gene We examined the histone acetylation around the p21 gene promoter, a modulator of the cell cycle (Hovhannisyan et al., 2003; Sakajiri et al., 2005) . Induction of monocytic differentiation by incubating HL-60 cells in medium containing auroanofin and 1,25(OH) 2 vit D 3 increased the acetylation of histone H3 at the p21 promoter (Figure 8b) . Consistent with this, the transcriptional level of p21 also increased (Figure 8c ). These observations suggest that the stimulatory effect of combined treatment with auroanofin and 1,25(OH) 2 vit D 3 on monocytic differentiation is related to the cooperative actions of the two compounds on chromatin remodelling through histone acetylation of the target genes.
Discussion
In a previous study, we found that auroanofin enhanced granulocytic differentiation of the NB4 cell line when combined with a subeffective dose of ATRA (Kim et al., 2004) . To identify whether auroanofin also stimulates the differentiation of primary APL cells, we purified fresh APL cells from the bone marrow of APL patients. We found that auroanofin reinforces the granulocytic differentiation of primary APL cells induced incompletely by a suboptimal dose of ATRA (10 nM) (Figures 1 and 2 ). When we obtained APL cells from the bone marrow of a patient undergoing ATRA treatment in the clinic, about 75% of the cells had become positive for CD11b expression after treatment with auroanofin (0.5 mM) alone, whereas 22% of cells were positive in untreated cells (data not shown). These findings suggest that auroanofin can prompt the differentiation of APL cells triggered by ATRA.
The PML-RARa fusion protein is one target of APL therapy, because the fusion protein is characteristic of APL cells and plays a crucial role in the pathogenesis of APL (Kakizuka et al., 1991; Grignani et al., 1993; Dyck et al., 1994) . In fact, ATRAinduced APL differentiation is associated with degradation of the PML-RARa protein and subsequent reorganization of PML bodies. We examined whether auroanofin participated in the degradation of the PML-RARa protein and the reformation of PML bodies. In immunocytochemical results (Figure 3) , the cells treated with both auroanofin and a suboptimal concentration of ATRA (10 nM) clearly showed speckled nuclear structures, which represented the formation of PML bodies. In addition, the combined treatment with auroanofin and ATRA induced degradation of PML-RARa. However, the degradation of PML-RARa was not sufficient to explain the mechanism underlying auroanofin-stimulated APL differentiation, because cotreatment with auroanofin and ATRA also induced the differentiation of HL-60 cells, which have no PML-RARa fusion protein (data not shown).
When HL-60 cells were cotreated with auroanofin and subeffective concentrations of 1,25(OH) 2 vit D 3 (3 nM), the stimulatory effects of auroanofin on monocytic differentiation were similar those of auroanofin-stimulated granulocytic differentiation in NB4 cells triggered by subeffective concentrations of ATRA. These results suggest that auroanofin acts on a common pathway of differentiation induced by ATRA and 1,25(OH) 2 vit D 3 . Both ATRA and 1,25(OH) 2 vit D 3 transduce signals through their ligand-inducible nuclear receptors and upregulate gene expression associated with differentiation by induction of histone acetylation at the promoter regions of the target genes (Kliewer et al., 1992; Guidez et al., 1998 (Figures  4 and 8) . Therefore, it is likely that auroanofin induced differentiation of APL cells by stimulating chromatin remodelling, which caused expression of genes involved in cell differentiation.
Taken together, this study demonstrates that auroanofin in the concentration range of 0.3-0.5 mM cooperatively induces the differentiation of APL cells along the granulocytic lineage when given with suboptimal concentrations of ATRA (10 nM) or along the monocytic lineage when given with a suboptimal concentrations of 1,25(OH) 2 vit D 3 (3 nM). Auroanofin exerts its differentiation-promoting activity through mechanisms that stimulate the reformation of PML bodies (possibly through degradation of PML-RARa fusion protein), histone acetylation around the promoter regions of genes involved in differentiation and cell cycle arrest. Pharmacological high doses of ATRA or 1,25(OH) 2 vit D 3 present problems when applied clinically, such as drug resistance or hypercalcemia (Warrell et al., 1993; Hisatake et al., 1999; Douer, 2002) . Our findings suggest that a combination of auroanofin with a low dose of ATRA or 1,25(OH) 2 vit D 3 may have therapeutic benefit in treating PML, without the harmful side effects caused by high doses of the drugs. 
